StarZero All shows Try the podcast clipper →

Laura Deming

Co-Founder & CEO, Until · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

investorfounderexecutivescientist@LauraDeming ↗LinkedIn ↗untillabs.com ↗Wikipedia ↗

After studying at MIT and receiving an inaugural Thiel Fellowship, Deming launched The Longevity Fund to back anti-aging biotechnology companies. She currently serves as co-founder and CEO of Until, developing reversible cryopreservation technology.

10statements → 2claims → 2claims resolved → 3.9/5average certainty → 2.4/5average debate potential → ≈4.5/5argument clarity, estimated → 3said about them ↓

2 supported 0 partly supported 0 contradicted how the 2 claims stand · each chip opens the sources

2 assertions · 3 opinions · 3 insights · 2 disclosures · every statement was checked. The predictions and assertions are the 2 claims: statements the public record can support or contradict. 2 are resolved. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Laura argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Deming: Biotech VC funding doubled while new startup creation remained flat
“I think one of the founding into biotech venture capital has doubled over the past couple years, and that's a huge fact, but the number of companies started to stay fairly stable”
Laura Deming Nov 26, 2018 ▶ 7:20 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund

How they sound: speaking style how? →

264 words/min while actually speaking · 6 um and uh per 1k words

No argument clarity score for Laura Deming: no usable question→answer exchanges on raw tape (a fair score needs 8+). We do not score a sample that small. Roundtable and news formats yield far fewer direct exchanges than interviews. Their coarse estimate from 24 exchanges on the produced feed is ≈4.5/5, shown at half point precision because the sample is small and produced tape scores higher.

Measured by listening to 4,311 words across 1 episode, but every recording we have of Laura Deming is the aired feed, and an editor cleaned that audio before release. Some of the hesitation was cut before we ever heard it, so read these as floors: the true rates are at least this high. These are measurements of speaking style, not scores. How it's measured →

How the interview went all their pushback → series average →

Across 1 rated episode:

host pushback ▾ 3/10
pushed back at the host 3/10
setup questions received 55%

Everything Laura Deming said on 20VC that made the record, most notable first. Filter by type, assessment or year in the ledger →

Opinion
Deming: Longevity is counterintuitively the least risky sector in biology
“I literally thought it was the least risky, most likely to work part of biology in general, particularly the part of biology that would be easy to test in humans, and that's very counterintuitive to most people.”
Laura Deming Nov 26, 2018 ▶ 12:52 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Insight
Deming: Biotech VC is constrained by founder talent, not funding
“And so I think the fascinating thing is, you know, I always assumed from the outside that biotech venture capital was really limited by dollars, and I think it used to be, but I think the fascinating fact is now it's all about talent, and just, you know, we're…”
Laura Deming Nov 26, 2018 ▶ 7:42 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Insight
Deming: Biotech value stems from founder-driven decisions, not initial thesis
“And I think, you know, maybe sometimes focusing on the thesis of an investment can blind you to the fact that most of the value in biotech comes from the eventual trajectory of the company that's unpredictable at the start. And that trajectory is absolutely di…”
Laura Deming Nov 26, 2018 ▶ 16:14 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Assertion Supported
Deming: Biotech VC funding doubled while new startup creation remained flat
“I think one of the founding into biotech venture capital has doubled over the past couple years, and that's a huge fact, but the number of companies started to stay fairly stable”
Laura Deming Nov 26, 2018 ▶ 7:20 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Disclosure
Deming: All Longevity Fund portfolio companies target multi-disease pathways
“All the companies that we invest in have drugs that have worked not just in kind of mouse models of Alzheimer's typically, but also diabetes and heart disease, and kind of typically the pathways that we invest in have been tested in and work in almost every Ag…”
Laura Deming Nov 26, 2018 ▶ 13:16 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Opinion
Deming: VC value creation is limited by rigid fund structure norms
“I think the diversity of fun types. I think we've been artificially constrained by a perception that it's hard to raise a new structure of fun because LPs just kind of, like, amorphously won't like it. I think that's really cut down on the value to be created …”
Laura Deming Nov 26, 2018 ▶ 26:15 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Assertion Supported
Laura Deming: Three decades of research prove aging is genetically malleable
“There was really very little work on aging and longevity, but the past three decades have resulted in massive advances. So we now know that it's possible to genetically control aging, that aging is malleable.”
Laura Deming Nov 26, 2018 ▶ 4:48 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Opinion
Deming: Internal biotech studio builds yield higher equity and easier LP pitches
“I mean, I think it's a great strategy. It's great for the VCs for certain parameters. I think the likelihood of success is slightly higher. The equity stakes are definitely higher, and there's a better pitch to LPs in the short term.”
Laura Deming Nov 26, 2018 ▶ 14:47 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Insight
Laura Deming: Raising a first VC fund is like a seed round
“But I think the process for raising your first fund is a lot more like raising a seed round for a company than it is like any kind of mature venture fundraising process I've seen.”
Laura Deming Nov 26, 2018 ▶ 18:23 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Disclosure
Laura Deming: The Longevity Fund pitched Unity Biotechnology to secure early LPs
“We had just found one of the first companies that we ever invested in, Unity Biotechnology, and we were really, really excited about them. And so I actually used that as the first Deal that I discussed with LPs.”
Laura Deming Nov 26, 2018 ▶ 19:47 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund

The other half of the tape: Laura Deming's own voice is left out of every number here. Other people bring the name up 3 times in 2 episodes on 20VC. every mention, with the transcript →

Who brings them up most Fred Turner 2Dylan Field 1

Every mention by year

tap a year for its mentions
0011212020202120222023202420252026episodesmentions
0112020202120222023202420252026episodes it came up in
0010.5212020202120222023202420252026episodesmentions per episode
2026 2 mentions in 1 episode
2020 1 mention in 1 episode

Appearances (1)

EpisodeDateSpeaking time
20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Diff Nov 26, 2018 16m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,200 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more